日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Defining the mode of action of cisplatin combined with NUC-1031, a phosphoramidate modification of gemcitabine

阐明顺铂与吉西他滨磷酰胺化修饰物NUC-1031联合用药的作用机制

Dillum Patel ,Alison L Dickson ,Greice M Zickuhr ,In Hwa Um ,Oliver J Read ,Clarissa M Czekster ,Peter Mullen ,David J Harrison ,Jennifer Bré

The novel anti-cancer fluoropyrimidine NUC-3373 is a potent inhibitor of thymidylate synthase and an effective DNA-damaging agent

新型抗癌氟嘧啶 NUC-3373 是胸苷酸合酶的强效抑制剂,也是一种有效的 DNA 损伤剂

Jennifer Bré, Alison L Dickson, Oliver J Read, Ying Zhang, Fiona G McKissock, Peter Mullen, Peijun Tang, Greice M Zickuhr, Clarissa M Czekster, David J Harrison

Collateral-resistance to estrogen and HER-activated growth is associated with modified AKT, ERα, and cell-cycle signaling in a breast cancer model

乳腺癌模型中对雌激素和 HER 激活生长的附带抵抗与 AKT、ERα 和细胞周期信号的改变有关

Kate M Moore #, Vera Cerqueira #, Kenneth G MacLeod #, Peter Mullen, Richard L Hayward, Simon Green, David J Harrison, David A Cameron, Simon P Langdon

Barriers to Use of Palliative Care and Advance Care Planning Discussions for Patients With End-Stage Liver Disease

终末期肝病患者接受姑息治疗和进行预立医疗照护计划讨论的障碍

Ufere, Nneka N; Donlan, John; Waldman, Lauren; Dienstag, Jules L; Friedman, Lawrence S; Corey, Kathleen E; Hashemi, Nikroo; Carolan, Peter; Mullen, Alan C; Thiim, Michael; Bhan, Irun; Nipp, Ryan; Greer, Joseph A; Temel, Jennifer S; Chung, Raymond T; El-Jawahri, Areej

Genome-scale CRISPR/Cas9 screen determines factors modulating sensitivity to ProTide NUC-1031

基因组规模的 CRISPR/Cas9 筛选确定了影响 ProTide NUC-1031 敏感性的因素

Awa Sarr, Jennifer Bré, In Hwa Um, Tsz Huen Chan, Peter Mullen, David J Harrison, Paul A Reynolds

Inhibition of pH regulation as a therapeutic strategy in hypoxic human breast cancer cells

抑制 pH 调节作为缺氧人类乳腺癌细胞的治疗策略

James Meehan, Carol Ward, Arran Turnbull, Jimi Bukowski-Wills, Andrew J Finch, Edward J Jarman, Chrysi Xintaropoulou, Carlos Martinez-Perez, Mark Gray, Matthew Pearson, Peter Mullen, Claudiu T Supuran, Fabrizio Carta, David J Harrison, Ian H Kunkler, Simon P Langdon

Antitumour activity of the novel flavonoid Oncamex in preclinical breast cancer models

新型黄酮类化合物 Oncamex 在临床前乳腺癌模型中的抗肿瘤活性

Carlos Martínez-Pérez, Carol Ward, Arran K Turnbull, Peter Mullen, Graeme Cook, James Meehan, Edward J Jarman, Patrick I T Thomson, Colin J Campbell, Donald McPhail, David J Harrison, Simon P Langdon

The role of HDAC2 in chromatin remodelling and response to chemotherapy in ovarian cancer

HDAC2 在卵巢癌染色质重塑和化疗反应中的作用

Rui Huang, Simon P Langdon, Matthew Tse, Peter Mullen, In Hwa Um, Dana Faratian, David J Harrison

Evaluation of carbonic anhydrase IX as a therapeutic target for inhibition of breast cancer invasion and metastasis using a series of in vitro breast cancer models

使用一系列体外乳腺癌模型评估碳酸酐酶 IX 作为抑制乳腺癌侵袭和转移的治疗靶点

Carol Ward, James Meehan, Peter Mullen, Claudiu Supuran, J Michael Dixon, Jeremy S Thomas, Jean-Yves Winum, Philippe Lambin, Ludwig Dubois, Nanda-Kumar Pavathaneni, Edward J Jarman, Lorna Renshaw, In Hwa Um, Charlene Kay, David J Harrison, Ian H Kunkler, Simon P Langdon

Model-based global sensitivity analysis as applied to identification of anti-cancer drug targets and biomarkers of drug resistance in the ErbB2/3 network

基于模型的全局敏感性分析在 ErbB2/3 网络中识别抗癌药物靶点和耐药性生物标志物中的应用

Galina Lebedeva, Anatoly Sorokin, Dana Faratian, Peter Mullen, Alexey Goltsov, Simon P Langdon, David J Harrison, Igor Goryanin